While clinical factors, such as Gleason Score and prostate-specific antigen (PSA) levels, have proven useful for risk stratification and in guiding treatment decisions about PCa, significant clinical heterogeneity remains [1]. Here, KLK3 is linked to posterior cortical atrophy.